With Factor VIIa Tie-up, Wyeth And Catalyst Look To Take On Novo Nordisk
This article was originally published in The Pink Sheet Daily
Executive Summary
In their second collaboration, the pharma and the biotech aim to develop a longer-acting, more potent hemophilia drug.